The evolving literature of the role of ADAMTS13 in other prothrombotic health conditions, affecting larger numbers of the population experiencing myocardial ischaemia, cerebrovascular disease and infections such as COVID-19, confirm the importance of this enzyme in regulating haemostasis, and its value as a target for novel therapies. This evidence concerns the gene ADAMTS13 and COVID-19.